External Automatic Glaucoma Laser
(EAGLE) for the first-line glaucoma treatment: Commercial prototype development and validation

 

The GLAUrious project is clinically testing and validating the novel External Automatic Glaucoma Laser (EAGLE) device developed and patented by BELKIN Laser Ltd with the goal of providing accessible first-line treatment for glaucoma. About 80 million people worldwide suffer from glaucoma, which is a chronic disease causing progressive optic nerve degeneration and is the leading cause of irreversible blindness globally. Although incurable, disease progression can be arrested or delayed by reducing the pressure inside the eye, thus preventing visual incapacitation and blindness.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement

No 720274

Current first-line treatment requires life-long daily eye drops, a strict regimen causing 50% patient dropout after 1 year.

News 

Please reload

GLAUrious Consortium Holds the Consortium Meeting, London, UK

January 27, 2020

1/5
Please reload

Dear consortium member,
If you wish to have access to the
following information:

  • Meetings

  • Management

  • Deliverables

  • Reports

Last News  

Please reload

  web design: STUDIO81

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement

No 720274